Insulin formulations - A review

European Review for Medical and Pharmacological Sciences

Volumn 5, Issue 3, 2001, Pages 73-83

  Gualandi Signorini, A M ^a   Giorgi, G ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Aspart; Glargine; Human insulin; Inhaled insulin; Lyspro; Oral insulin

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN RECEPTOR; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; SOMATOMEDIN C;

CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESPONSE; INSULIN TREATMENT; LUNG ALVEOLUS; PANCREAS ISLET BETA CELL; POLYMERIZATION; POSTPRANDIAL STATE; POWDER; RECOMBINANT DNA TECHNOLOGY; REVIEW;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; HISTORY, 20TH CENTURY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RECOMBINANT PROTEINS;

EID: 0035568824     PISSN: 0392291X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. The internal secretion of the pancreas
2. Pancreatic extracts
3. The first clinical use of insulin
4. Protamine insulinate
5. Crystalline protamine insulin
6. The lente insulins
7. Chemistry of insulin
8. Immunoassay of insulin with insulin-antibody precipitate
9. Human monocomponent insulin. Chemistry and characteristics
10. The synthesis of the insulin chains and their combination to biologically active material
11. Semisynthesis of human insulin by trypsin-catalyzed replacement of Ala-B30 by Thr in porcine insulin
12. Human insulin (Novo): Chemistry and characteristics
13. Expression in Escherichia coli of chemically synthesized genes for human insulin
14. Recombinant DNA: A new source of insulin
15. Chemical, physical and biological properties of biosynthetic human insulin
16. The production of human proinsulin and its transformation to human insulin and C-peptide
17. Authenticity purity of human insulin
18. Biosynthetic human proinsulin: Review of chemistry, in vitro and in 'vivo receptor binding, animal and human pharmacology studies, and clinical experience
19. Production of human monocomponent insulin
20. Biosynthesis of human insulin in yeast via single chain precursors
21. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens
22. Insulin pharmacokinetics
23. Monomeric insulins and their experimental and clinical implications
24. [Lys(B28), Pro(B29)] human insulin. A rapidly absorbed analogue of human insulin
25. Altering the association properties of insulin by aminoacid replacement
26. Synthesis of fast acting insulin based on structural homology with insulin-like growth factor I
27. The structure of 2Zn pig insulin crystals at 1.5 A resolution
28. Insulin preparations
29. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analogue in IDDM of short duration with residual pancreatic b-cell function
30. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes
31. A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen
32. Postprandial use of insulin lispro: A new therapeutic option in the treatment of type 1 diabetic patients?
33. Optimal combination of insulin lispro and basal insulin improves glycemic control in IDDM
34. Reduction of postprandial hyperglycemia and frequency hypoglycemia in IDDM patients on insulin-analogue treatment
35. Pizza, coke and tiramisu: Can type 1 diabetic patients cover such a meal with the rapid acting insulin analogue Lyspro
36. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro
37. Preclinical safety pharmacology studies on the rapid-acting insulin analogue, insulin aspart
38. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency
39. Pharmacokinetics of insulin aspart, a short acting insulin analogue in rats and dogs
40. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers
41. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up
42. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
43. Impaired glucose tolerance, type 2 diabetes mellitus and carotid atherosclerosis. Prospective results from the Bruneck Study
44. Uso dell'analogo dell'insulina lispro nella terapia intensiva del diabete mellito di tipo 1
45. Razionale della terapia insulinica nel diabete di tipo II
46. The effect of intensive treatment of diabetes on the development and the progression of long-term complications in insulin-dependent diabetes mellitus
47. Evening insulin strategy
48. New insulin preparations with prolonged action profiles: A21-modified arginine insulin
49. Absorption and effect profile after s.c. administration of the long-acting insulin NN-304 to pigs
50. Long-acting insulin analogs
51. Human insulin analog HOE 901: Characteristics of receptor binding and tyrosine kinase activation
52. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
53. 24h profile of action of biosynthetic long-acting insulin (HOE 901) tested in normal volunteers by glucose clamp methodology
54. Time-action profile of long-acting insulin analogue HOE 901
55. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE 901 compared with NPH and ultralente human insulins using the euglycaemic clamp technique
56. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog Glargine, NPH insulin, ultralente human insulin and continuous subcutaneous infusion of insulin lispro
57. Time-action profile of the long-acting insulin analog glargine (HOE 901) in comparison with those of NPH insulin and placebo
58. Pharmacokinetics of a long-acting human insulin analog (HOE 901) in healthy subjects
59. Comparison of the sc absorption of HOE 901 and NPH human insulin in type 2 diabetic subjects
60. The European Study Group of HOE 901 in type 1 diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes
61. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes
62. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens
63. Safety of insulin glargine
64. Glycerol prevents insulin precipitation and interruption of flow in an implantable insulin infusion pump
65. Insulin aggregation in artificial delivery systems
66. Nonaggregating insulin solutions for long-term glucose control in experimental and human diabetes
67. Simple solution to problem of biostator-induced insulin aggregation
68. Chemical stability of insulin: 2. Formation of higher molecular weight transformation products during storage of pharmaceutical insulin preparations
69. Variation in 125I-insulin absorption and blood glucose concentration
70. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations
71. Massage-enhanced insulin absorption - Increased distribution or dissociation of insulin
72. Pharmacokinetic considerations of new insulin formulations and routes of administration
73. The insulin
74. Chemical and pharmaceutics of insulin
75. Uber Inhalation von Insulin
76. Insulin. Its chemistry and physiology
77. Mechanisms of macromolecule absorption by the lungs
78. Inhaled insulin
79. Two cheers for inhaled insulin
80. 1999: New approaches to insulin treatment and glucose monitoring
81. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (NIDDM)
82. Insulin therapy in children and adolescents with type 1 diabetes
83. Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study
84. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes